Targets › MARV
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Infectious disease; next expected readout Apr 2027.
Open in Phaseline: the race on MARV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Albert B. Sabin Vaccine Institute | cAd3-Marburg Vaccine chimpanzee adenovirus Type 3-vectored vaccine expressing Marburg wild type glycoprotein fr | MARV | Phase 2 | Marburg Virus Disease | – |
| International AIDS Vaccine Initiative | rVSV∆G-MARV-GP Recombinant vesicular stomatitis virus expressing Marburg virus glycoprotein | MARV | Phase 1 | Marburg Virus Disease | Apr 2027 |
Marburg Virus Disease (2)
protein or peptide (1), other (1)
International AIDS Vaccine Initiative (1) Albert B. Sabin Vaccine Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.